Celgene Corp - Company Profile
Powered by 
All the data and insights you need on Celgene Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Celgene Corp Strategy Report
- Understand Celgene Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Celgene Corp Catalyst Calendar
Proactively evaluate Celgene Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Celgene Corp Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 25 Sep 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 12 Sep 2019 | Phase II Trial Completion | Celgene Corp; Receptos Inc | - | ozanimod hydrochloride | Gastrointestinal | Crohn's Disease (Regional Enteritis) | Clinical Trial Registry |
| 01 Sep 2019 | Phase II/III Trial Completion | Amgen Inc; AOK Rheinland-Hamburg; Bayer AG; Celgene Corp; F. Hoffmann-La Roche Ltd; Genomic Health Inc; Teva Pharmaceutical Industries Ltd; Westdeutsche Studiengruppe GmbH | AMGN; BAYN; ROG; TEVA | carboplatin; cyclophosphamide; docetaxel; doxorubicin; epirubicin hydrochloride; exemestane; paclitaxel albumin bound; pertuzumab; trastuzumab; trastuzumab emtansine | Oncology | Breast Cancer; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) | Clinical Trial Registry |
| 29 Aug 2019 | Phase II Trial Completion | Celgene Corp; Dana-Farber/Harvard Cancer Center; Massachusetts General Hospital | - | lenalidomide | Oncology | Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia); Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer